

Item S1. Search Strategy

Database: Ovid, MEDLINE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials until July 18th, 2015

1. nephrotic.mp.
2. Nephrosis/ or Nephrosis.mp.
3. Nephrosis, Lipoid/ or Nephrosis/
4. Minimal change disease.mp.
5. Focal segmental glomerulosclerosis.mp.
6. FSGS.mp.
7. Membranous nephropathy.mp.
8. Nephropathy.mp.
9. Nephritis.mp.
10. Glomerulonephritis.mp.
11. Glomerulonephropathy.mp.
12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. Acthar.mp.
14. ACTH.mp.

15. adrenocorticotropic.mp.

16. 13 or 14 or 15

17. 12 and 16

18. limit 17 to humans

Table S1. Summary of Studies of Adrenocorticotrophic Hormone Therapy in other glomerular diseases

Author	Number of Patients	Immunosuppression Response Category	ACTH Preparation	Total Dose (per week)	Duration of Treatment (months)	Follow-up Duration (month)	CR	PR	NR	Early Termination
IgA nephropathy										
Khastgir et al (2015) [25]***	5	1 IR/ 4 naïve	Natural	160 U	> 6	> 6	0	2	2	1
Madan et al (2014) [24]**	5	NA	Natural	160 U	> 6	> 6	0	1	3	1
Bomback et al (2012)[5] **	5	NA	Natural	160 U	6	6	1	1	2	1
Bomback et al (2011)[4] **	1	1 naïve	Natural	80 U	8	8	1	0	0	0
Lupus nephritis										
Khastgir et al (2015) [25]***	2	2 IR	Natural	160 U	> 6	> 6	0	2	0	0
Madan et al (2014)[24] **	1	NA	Natural	160 U	> 6	> 6	0	1	0	0
Berg et al (2013)[21] ***	5	2 naïve	Synthetic	2 mg	6 (2-18)	24 (6-72)	NA	NA	NA	0
Bomback et al (2011) [4]**	1	1 naïve	Natural	80 U	5	8	0	0	1	0
MPGN										
Lorusso et al (2015)[7] *	3	NA	Synthetic	1 mg	12	48	1	0	1	1
Madan et al (2014)[24] **	1	NA	Natural	160 U	> 6	> 6	0	0	1	0
Bomback et al S (2011)[4] **	4	4 IR	Natural	120-160 U	5 (4-6)	6 (6-8)	0	0	4	0
Diabetic nephropathy										
Madan et al (2014)[24] **	2	NA	Natural	160 U	> 6	> 6	0	0	1	0
Tumlin et al (2013) [23]*	14	NA	Natural	112-224 U	6	6	1	7	0	0
Berg et al (2004)[27] **	2	NA	Synthetic	0.5-2 mg	5.5 (5-6)	18 (12-24)	0	2	0	0

ACTH, adrenocorticotrophic hormone; CR, complete response; IR, immunosuppression resistant (other than steroids); NA, data not available; NR, no response; PR partial response.

* CR defined as urine protein excretion <300 mg/day; PR defined as >50% reduction of proteinuria and urine protein excretion <3.5 g/day.

** CR defined as urine protein excretion <500 mg/day; PR defined as >50% reduction of proteinuria and urine protein excretion <3.5 g/day.

*** Response criteria were not provided.

Figure S1. Forest Plots of Incidence Rates of Adverse Effects




Figure S1. Forest Plots of Incidence Rates of Adverse Effects (continue)




Figure S1. Forest Plots of Incidence Rates of Adverse Effects (continue)




Figure S2. Funnel Plots Showing Logarithmized Incidence Rate of Side Effects.

